Everything below concerns Certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
=== 1971–present: the "war on drugs" === On May 27, 1971, after a trip to Vietnam, two congressmen, Morgan F. Murphy (Democrat) and Robert H. Steele (Republican), released a report describing a "rapid increase in heroin addiction within the United States military forces in South Vietnam". They estimated that "as many as 10 to 15 percent of our servicemen are addicted to heroin in one form or another." On June 6, a New York Times article, "It's Always A Dead End on 'Scag Alley'", cited the Murphy-Steele report in a discussion of heroin addiction. The article stated that, in the US, "the number of addicts is estimated at 200,000 to 250,000, only about one‐tenth of 1 per cent of the population but troublesome out of all proportion." It also noted, "Heroin is not the only drug problem in the United States. 'Speed' pills – among them, amphetamines – are another problem, and not least in the suburbs where they are taken by the housewife (to cure her of the daily 'blues') and by her husband (to keep his weight down)." On June 17, 1971, Nixon presented to Congress a plan for expanded anti-drug abuse measures. He painted a dire picture: "Present efforts to control drug abuse are not sufficient in themselves. The problem has assumed the dimensions of a national emergency. ...
Once the tobacco is cured, workers tie it into small bundles of about 20 leaves, called hands, or use a machine to make large blocks, called bales. The hands or bales are aged for one to three years to improve flavor and reduce bitterness.
=== Chief executives === 1907–1962, James E. "Jim" Casey 1962–1972, George D. Smith 1972–1973, Paul Oberkotter 1973–1980, Harold Oberkotter 1980–1984, George Lamb 1984–1989, John W. Rogers 1989–1996, Kent C. "Oz" Nelson 1997–2001, James P. Kelly 2002–2007, Michael L. "Mike" Eskew 2008–2014, Scott Davis 2014–2020, David Abney 2020–current, Carol B. Tomé
This is a list of Ice Age species preserved as permafrost mummies during the Late Pleistocene. It includes all known species that have had their tissues partially preserved within the permafrost layer of the Arctic and Subarctic. Most went extinct during the Late Pleistocene extinctions while some are still extant today. They have been listed to the most specific known taxonomic rank.
ArH + CH2O → ArCH2OH When conducted in the presence of hydrogen chloride, the product is the chloromethyl compound, as described in the Blanc chloromethylation. If the arene is electron-rich, as in phenols, elaborate condensations ensue. With 4-substituted phenols one obtains calixarenes. Phenol results in polymers.
Sources: en.wikipedia.org
Prior to that, at a rally in Alor Setar, he had similarly urged Anwar to step down, citing mismanagement of national wealth and poor governance. In December 2025, Mahathir lodged a police report accusing Anwar of economic sabotage and undermining Malaysia's sovereignty over the Malaysia–United States Agreement on Reciprocal Trade (ART), an agreement that later sparked public controversy over provisions seen by critics as obliging Malaysia to align with US sanctions, compromise regulatory autonomy, and weaken the country's long-standing policy of non-alignment. In early January 2026, Mahathir was admitted to the National Heart Institute (IJN) for observation after he fell at his residence and was taken to hospital by ambulance. Hospital officials later confirmed that he had sustained a fracture to his right hip and remained in stable condition while receiving treatment. According to his son, Mukhriz Mahathir, medical specialists advised that he was not suitable for hip replacement surgery due to age-related risks, and that a non-surgical recovery approach would be adopted. Mahathir's hospitalisation attracted significant domestic and international attention, with Turkish President Recep Tayyip Erdoğan conveying his concern and well wishes during a meeting with Prime Minister Anwar Ibrahim while the latter was on an official visit to Turkey. On 29 September, the day after his wife Siti Hasmah died, Mahathir was hospitalized at the National Heart Institute in Kuala Lumpur.
=== LeukoSite === Springer has played a prominent role in biotechnology. His scientific and entrepreneurial work has contributed to multiple FDA-approved therapies in immunology, oncology, and rare diseases, and he has been an influential early investor and company founder in the life sciences industry. In the early 1990s, Springer founded LeukoSite to develop therapeutics based on leukocyte adhesion and trafficking biology. LeukoSite’s programs advanced or incorporated three agents that ultimately became approved medicines: vedolizumab (Entyvio), a humanized antibody targeting integrin α4β7 for inflammatory bowel disease; bortezomib (Velcade) for multiple myeloma and mantle cell lymphoma; and alemtuzumab (Campath-1/Lemtrada) for B-cell chronic lymphocytic leukemia and multiple sclerosis. Millennium Pharmaceuticals acquired LeukoSite in late 1999 by issuing shares; after the merger, LeukoSite shareholders owned 35% of Millennium stock. LeukoSite’s antibody program targeting integrin α4β7 was the foundation for vedolizumab (Entyvio), approved by the FDA in 2014 for ulcerative colitis and Crohn’s disease. Entyvio has since become a major product in the immunology space: Takeda, which acquired the asset through its purchase of Millennium, reported Entyvio revenue of JPY 914.1 billion, approximately US$6.1 billion, for the fiscal year ended March 31, 2025. More than 350,000 patients have been treated with Entyvio since 2014 in the U.S., based on Symphony claims data (June 2014-Jan 2025). Takeda has described Entyvio as a cornerstone of its portfolio.
=== Acquisition by Take-Two Interactive (2024–present) === Take-Two Interactive announced its plans to acquire Gearbox Entertainment and its intellectual properties from Embracer Group for $460 million on March 28, 2024, to be added under the 2K label. The acquisition also includes Gearbox Software with its satellite studios and Gearbox Publishing. Embracer will retain Gearbox San Francisco, Gearbox Shanghai, Lost Boys Interactive, Captured Dimensions, and Cryptic Studios, along with publishing rights to Remnant, Hyper Light Breaker, and other unannounced titles. Less than a day after the announcement, it was reported that an unknown number of employees were laid off from Gearbox. On June 12, 2024, Take-Two Interactive closed the Gearbox Software transaction.
Ethylene oxide is a surface disinfectant that is widely used in hospitals and the medical equipment industry to replace steam in the sterilization of heat-sensitive tools and equipment, such as disposable plastic syringes. It is so flammable and extremely explosive that it is used as a main component of thermobaric weapons; therefore, it is commonly handled and shipped as a refrigerated liquid to control its hazardous nature.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.